Holen Sie sich die Stockscreener-App
23.75
4.29%
-1.065
Schlusskurs vom Vortag:
$24.82
Offen:
$25.08
24-Stunden-Volumen:
1.00M
Relative Volume:
0.78
Marktkapitalisierung:
$2.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-15.32
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
-9.87%
1M Leistung:
+3.35%
6M Leistung:
+82.55%
1J Leistung:
-12.13%
1-Tages-Spanne:
$23.66
$25.08
1-Wochen-Bereich:
$23.66
$26.54
52-Wochen-Spanne:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
23.75 | 2.63B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits - The Globe and Mail
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
What drives Edgewise Therapeutics Inc stock priceHigh Dividend Yield Stocks & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2%Here's Why - MarketBeat
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ts2.tech
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - BioSpace
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout - Stocktwits
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance
Edgewise Stock (+26%): Phase 2 HCM Safety Data Forces a Re-Rate - Trefis
Why Edgewise Therapeutics Stock Rocked the Market Today - Finviz
Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating - TipRanks
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics rises on positive safety data from heart disease drug trial - TradingView — Track All Markets
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Edgewise reports positive interim safety data for HCM drug EDG-7500 - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update By Investing.com - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update - Investing.com
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRU - GuruFocus
Edgewise Completed Phase 2 CIRRUS-HCM Parts B And C, Reports Favorable Interim Safety From Part D - Nasdaq
Edgewise Therapeutics Completes Parts B and C of Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Edgewise reports positive interim safety data for HCM drug EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc on track to deliver full 12-week part D readout in 2Q 2026 and phase 3 start in 4Q 2026 - marketscreener.com
Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026 - TradingView — Track All Markets
Edgewise Therapeutics Announces Completion of the EDG-7500 Cirrus-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - marketscreener.com
Insider Trends: Is Edgewise Therapeutics Inc stock vulnerable to regulatory risksQuarterly Profit Summary & Expert Curated Trade Setups - moha.gov.vn
Can Edgewise Therapeutics Inc. stock double in next 5 yearsLow Beta Stocks & Use Smart Algorithms to Pick Better Stocks - bollywoodhelpline.com
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025) - ts2.tech
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):